Sfoglia per AUTORE
TUCCI M
Collezione AO Ordine Mauriziano

  

Items : 32

Safety profile of darolutamide versus placebo: a systematic review and meta-analysis. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2024 Sep;27(3):385-392. doi: 10.1038/s41391-023-00775-y. Epub 2023 De
2024
ASL Asti
AO Ordine Mauriziano

Di Maio M; Buttigliero C; Cathomas R; Tombal B; Smith MR; Fizazi K; Treglia G; Gillessen S; Turco F; Tucci M; Vogl UM; Turco F; Gillessen S; Treglia G; Fizazi K; Smith MR; Tombal B; Cathomas R; Buttigliero C; Di Maio M; Tucci M; Vogl UM;

Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Oct;22(5):102138. doi: 10.1016/j.clgc.2024.102138. Epub 2024 Jun 12.
2024
ASL Asti
AO Ordine Mauriziano

Palesandro E; Di Maio M; Poletto S; Crespi V; Saporita I; Calabrese M; Farinea G; Di Stefano RF; Gallina A; Fossati N; Zilli T; Vogl UM; Gillessen S; Delcuratolo MD; Buttigliero C; Turco F; Scagliotti GV; Tucci M;

Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects. in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2024 Mar 1;32(3):202. doi: 10.1007/s00520-024-08392-8.
2024
ASL Asti
AOU Alessandria
AO Ordine Mauriziano

Cinieri S; Rossetti G; Airoldi M; Rossi M; Lanzetta G; Cavanna L; Ibrahim T; Bossi P; Santini D; Tucci M; De Giorgi U; Valsecchi AA; Comandone A; Di Maio M; Fusco V;

Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey. in Tumori / Tumori. 2024 Jun;110(3):174-185. doi: 10.1177/03008916241236279. Epub 2024 Mar 10.
2024
ASL Asti
AOU Alessandria
AO Ordine Mauriziano

Vignani F; Cinieri S; Dionisio R; De Giorgi U; Tucci M; Di Maio M; Santini D; Fusco V; Valsecchi AA;

TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Apr;22(2):56-67.e16. doi: 10.1016/j.clgc.2023.08.006. Epub 2023 Sep 7.
2024
ASL Cuneo 2
ASL Asti
ASL Città di Torino
AO Ordine Mauriziano

Tucci M; Maio MD; Ortega C; Vellani G; Airoldi M; Rossi M; Comandone A; Gennari A; Vormola R; Numico G; Depetris I; Stevani I; Buosi R; Vignani F; Dionisio R; Icardi M; Guglielmini P; Cattrini C; Vana F; Mennitto A; Prati V; Brusa F; Vanella P; Ruatta F; Filippi R; Turco F; Fea E; Arnaudo E; Pisano C; et alii...

Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2023 Jan;181:103881. doi: 10.1016/j.critrevonc.2022.103881. Epub 2022 Nov 24
2023
ASL Asti
AO Ordine Mauriziano

Buttigliero C; Di Maio M; Scagliotti GV; Brusa F; Audisio A; Samuelly A; Audisio M; Di Stefano RF; Ungaro A; Turco F; Tucci M; Delcuratolo MD;

2023
ASL Asti
AO Ordine Mauriziano

Di Maio M; Buttigliero C; Scagliotti GV; Ungaro A; Parlagreco E; Audisio M; Audisio A; Samuelly A; Pisano C; Urban S; Parente A; Di Stefano RF; Tucci M; Angusti T; Turco F;

New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine? in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2022 Jun;174:103682. doi: 10.1016/j.critrevonc.2022.103682. Epub 2022 Apr 11
2022
ASL Asti
AO Ordine Mauriziano

Scagliotti GV; Di Maio M; Ortega C; Di Prima L; Audisio A; Turco F; Ungaro A; Parlagreco E; Di Stefano RF; Tucci M; Audisio M; Buttigliero C;

2022
ASL Asti
AO Ordine Mauriziano

Scagliotti GV; Di Maio M; Delcuratolo MD; Turco F; Pisano C; Di Prima L; Audisio A; Tucci M; Ungaro A; Buttigliero C;

Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study. in Minerva urology and nephrology / Minerva Urol Nephrol. 2022 Dec;74(6):703-713. doi: 10.23736/S2724-6051.22.04701-2. Epub 2022 Feb 11.
2022
ASL Asti
AO Ordine Mauriziano

Tucci M; DI Maio M; Scagliotti GV; Pisano C; Samuelly A; Turco F; Bungaro M; Parente A; DI Stefano RF; Angusti T; Buttigliero C;

Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy. in Cancer communications (London, England) / Cancer Commun (Lond). 2022 Aug;42(8):683-688. doi: 10.1002/cac2.12340. Epub 2022 Jul 22.
2022
ASL Asti
AO Ordine Mauriziano

Scagliotti GV; Ortega C; Di Maio M; Ungaro A; Audisio M; Audisio A; Pisano C; Di Stefano RF; Tucci M; Delcuratolo MD; Turco F; Buttigliero C;

Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2021 Sep;24(3):812-825. doi: 10.1038/s41391-021-00336-1. Epub 2021 Fe
2021
ASL Asti
AO Ordine Mauriziano

Buttigliero C; Di Maio M; Gallicchio M; Scagliotti GV; Vignani F; Pisano C; Bungaro M; Samuelly A; Turco F; Tucci M; Di Stefano RF;

Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. in Endocrine-related cancer / Endocr Relat Cancer. 2021 Jun 2;28(7):R207-R216. doi: 10.1530/ERC-20-0457.
2021
ASL Asti
AO Ordine Mauriziano

Buttigliero C; Scagliotti GV; Di Maio M; Pisano C; Bungaro M; Audisio M; Samuelly A; Tucci M; Di Stefano RF; Turco F;

Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2021 Jan;157:103185. doi: 10.1016/j.critrevonc.2020.103185. Epub 2020 Nov 27
2021
ASL Asti
AO Ordine Mauriziano

Di Maio M; Buttigliero C; Scagliotti GV; Turco F; Di Stefano RF; Tucci M; Pisano C;

Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. in Minerva urology and nephrology / Minerva Urol Nephrol. 2021 Dec;73(6):803-814. doi: 10.23736/S2724-6051.21.04186-2. Epub 2021 Mar 29.
2021
ASL Asti
AO Ordine Mauriziano

Buttigliero C; DI Maio M; Scagliotti GV; Tarenghi F; Bungaro M; Vignani F; Samuelly A; Turco F; DI Stefano RF; Tucci M; Pisano C;

2021
ASL Asti
AO Ordine Mauriziano

Beretta GD; Cinieri S; Tucci M; Perrone F; La Verde N; Del Mastro L; Giuffrida D; De Giorgi U; Chiari R; Russo A; Di Maio M; Silvestris N;

2020
ASL Asti
AO Ordine Mauriziano

Tucci M; Necchi A; Gamba T; Buttigliero C; Vignani F; Marandino L; Di Maio M;

Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. in Minerva urologica e nefrologica = The Italian journal of urology and nephrology / Minerva Urol Nefrol. 2020 Dec;72(6):737-745. doi: 10.23736/S0393-2249.20.03708-X. Epub 2020 Apr 10.
2020
AOU Alessandria
AO Ordine Mauriziano

Numico G; Scagliotti GV; Guglielmini P; Lacidogna G; Turco F; Pisano C; Di Stefano RF; Vignani F; Sonetto C; Tucci M; Buttigliero C; Di Maio M;

Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2020 Aug;152:102994. doi: 10.1016/j.critrevonc.2020.102994. Epub 2020 May 24
2020
ASL Asti
AO Ordine Mauriziano

Di Maio M; Scagliotti GV; Vignani F; Turco F; Tabbò F; Di Stefano RF; Pisano C; Buttigliero C; Leone G; Tucci M;

Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2019 Oct;17(5):332-347.e2. doi: 10.1016/j.clgc.2019.07.007. Epub 2019 Jul 20
2019
AO Ordine Mauriziano

Marandino L; De Luca E; Zichi C; Lombardi P; Reale ML; Pignataro D; Di Stefano RF; Ghisoni E; Mariniello A; Trevisi E; Leone G; Muratori L; La Salvia A; Sonetto C; Buttigliero C; Tucci M; Aglietta M; Novello S; Scagliotti GV; Perrone F; Di Maio M;

Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. in Cancer treatment reviews / Cancer Treat Rev. 2019 Mar;74:35-42. doi: 10.1016/j.ctrv.2019.01.002. Epub 2019 Jan 7.
2019
AO Ordine Mauriziano

Tucci M; Caffo O; Buttigliero C; Cavaliere C; D'aniello C; Di Maio M; Kinspergher S; Maines F; Rizzo M; Rossetti S; Veccia A; Scagliotti GV; Facchini G;

Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. in Cancer treatment reviews / Cancer Treat Rev. 2018 Sep;69:215-223. doi: 10.1016/j.ctrv.2018.07.010. Epub 2018 Jul 20.
2018
AO Ordine Mauriziano

Buttigliero C; Allis S; Tucci M; Zichi C; Leone G; Di Stefano RF; Ruo Redda MG; Ricardi U; Scagliotti GV; Di Maio M; Filippi AR;

Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2018 Sep;129:124-132. doi: 10.1016/j.critrevonc.2018.07.004. Epub 2018 Jul 1
2018
AO Ordine Mauriziano

Di Nunno V; De Luca E; Buttigliero C; Tucci M; Vignani F; Gatto L; Zichi C; Ardizzoni A; Di Maio M; Massari F;

Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. in Endocrine-related cancer / Endocr Relat Cancer. 2018 Jan;25(1):R1-R9. doi: 10.1530/ERC-17-0355. Epub 2017 Sep 28.
2018
AO Ordine Mauriziano

Leone G; Tucci M; Buttigliero C; Zichi C; Pignataro D; Bironzo P; Vignani F; Scagliotti GV; Di Maio M;

Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2018 Dec;16(6):e1087-e1090. doi: 10.1016/j.clgc.2018.07.011. Epub 2018 Jul 2
2018
AO Ordine Mauriziano

Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M;

Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2018 Aug;16(4):318-324. doi: 10.1016/j.clgc.2018.05.006. Epub 2018 Jun 1.
2018
AOU Alessandria
AO Ordine Mauriziano

Scagliotti GV; Guglielmini P; Numico G; Lacidogna G; Pignataro D; Zichi C; Leone G; Di Stefano RF; Vignani F; Tucci M; Buttigliero C; Di Maio M;

Hormonal treatment and quality of life of prostate cancer patients: new evidence. in Minerva urologica e nefrologica = The Italian journal of urology and nephrology / Minerva Urol Nefrol. 2018 Apr;70(2):144-151. doi: 10.23736/S0393-2249.17.03066-1. Epub 2017 Dec 14.
2018
AO Ordine Mauriziano

Tucci M; Leone G; Buttigliero C; Zichi C; DI Stefano RF; Pignataro D; Vignani F; Scagliotti GV; DI Maio M;

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. in OncoTargets and therapy / Onco Targets Ther. 2018 Oct 24;11:7353-7368. doi: 10.2147/OTT.S153764. eCollection 2018.
2018
AO Ordine Mauriziano

Tucci M; Zichi C; Buttigliero C; Vignani F; Scagliotti GV; Di Maio M;

An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer. in Minerva urologica e nefrologica = The Italian journal of urology and nephrology / Minerva Urol Nefrol. 2017 Aug;69(4):349-358. doi: 10.23736/S0393-2249.16.02746-6. Epub 2016 Dec 22.
2017
AO Ordine Mauriziano

DI Maio M; Scagliotti GV; Berruti A; Buttigliero C; Aroasio E; Vignani F; Bertaglia V; Tucci M;

Zoledronic Acid Dosing Interval for Metastatic Cancer. in JAMA / JAMA. 2017 Apr 11;317(14):1477-1478. doi: 10.1001/jama.2017.2562.
2017
AO Ordine Mauriziano

Tucci M; Buttigliero C; Di Maio M;

Immediate or Delayed Nephrectomy in Patients With Metastatic Renal Cancer Who Are Receiving Targeted Agents: Is the Analysis at Risk for Guarantee-Time Bias? in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2017 Apr 10;35(11):1264. doi: 10.1200/JCO.2016.69.3580. Epub 2017 Feb 6.
2017
AO Ordine Mauriziano

Buttigliero C; Tucci M; Vignani F; Di Maio M;

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. in BioMed research international / Biomed Res Int. 2017;2017:5618174. doi: 10.1155/2017/5618174. Epub 2017 Jun 7.
2017
AO Ordine Mauriziano

Zichi C; Tucci M; Leone G; Buttigliero C; Vignani F; Pignataro D; Scagliotti GV; Di Maio M;

©2024 Tutti i diritti riservati. Biblioteca Virtuale per la Salute - Piemonte